10:47 AM EDT, 04/09/2024 (MT Newswires) -- Charles River Laboratories International ( CRL ) said Tuesday that it agreed to a plasmid DNA contract development and manufacturing organization collaboration with Axovia Therapeutics.

Under the collaboration, Charles River said it will use its eXpDNA platform to manufacture high-quality plasmid that will support Axovia's development of gene therapies for ciliopathies including Bardet-Biedl Syndrome.

No financial details were disclosed.

Price: 256.64, Change: +1.72, Percent Change: +0.67